<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhu B</submitter><funding>Youth Innovation Promotion Association of Chinese Academy of Sciences</funding><funding>Natural Science Foundation of Shanghai</funding><funding>National Natural Science Foundation of China</funding><pagination>e012044</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12336582</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(8)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Despite a series of attempts during the last decades, the prognosis for esophageal squamous cell carcinoma (ESCC) remains poor. Although clinical immunotherapy trials have shown encouraging results, their benefits are limited. This study aims to identify novel targets for immunotherapy in ESCC.&lt;h4>Experimental design&lt;/h4>ESCC cell lines and mouse models were used to identify the tumor-promoting function of pancreatic progenitor cell differentiation and proliferation factor (PPDPF) and evaluate the effect of blockade of CD24. RNA sequencing was performed to profile transcriptomic changes upon PPDPF deficiency. Fluorescence microscopy-based phagocytosis assay and flow cytometry were employed to analyze macrophage phagocytosis. Immunoblotting, glutathione S-transferase-pull</pubmed_abstract><journal>Journal for immunotherapy of cancer</journal><pubmed_title>PPDPF promotes the progression of esophageal squamous cell carcinoma via c-Myc/CD24 axis.</pubmed_title><pmcid>PMC12336582</pmcid><funding_grant_id>82172950</funding_grant_id><funding_grant_id>23ZR1482300</funding_grant_id><funding_grant_id>2017324</funding_grant_id><pubmed_authors>Liang X</pubmed_authors><pubmed_authors>Ma N</pubmed_authors><pubmed_authors>Long L</pubmed_authors><pubmed_authors>Qiu XS</pubmed_authors><pubmed_authors>Zhu B</pubmed_authors><pubmed_authors>Ding K</pubmed_authors><pubmed_authors>Wang YK</pubmed_authors><pubmed_authors>Cao HJ</pubmed_authors><pubmed_authors>Qiu L</pubmed_authors><pubmed_authors>Li ZG</pubmed_authors><pubmed_authors>Xiang YJ</pubmed_authors><pubmed_authors>Xia J</pubmed_authors><pubmed_authors>Huang JY</pubmed_authors><pubmed_authors>Ni QZ</pubmed_authors><pubmed_authors>Chen W</pubmed_authors><pubmed_authors>Xu S</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Zhang XR</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Liu ZC</pubmed_authors><pubmed_authors>Li JJ</pubmed_authors><pubmed_authors>Zheng QW</pubmed_authors><pubmed_authors>Yao F</pubmed_authors></additional><is_claimable>false</is_claimable><name>PPDPF promotes the progression of esophageal squamous cell carcinoma via c-Myc/CD24 axis.</name><description>&lt;h4>Background&lt;/h4>Despite a series of attempts during the last decades, the prognosis for esophageal squamous cell carcinoma (ESCC) remains poor. Although clinical immunotherapy trials have shown encouraging results, their benefits are limited. This study aims to identify novel targets for immunotherapy in ESCC.&lt;h4>Experimental design&lt;/h4>ESCC cell lines and mouse models were used to identify the tumor-promoting function of pancreatic progenitor cell differentiation and proliferation factor (PPDPF) and evaluate the effect of blockade of CD24. RNA sequencing was performed to profile transcriptomic changes upon PPDPF deficiency. Fluorescence microscopy-based phagocytosis assay and flow cytometry were employed to analyze macrophage phagocytosis. Immunoblotting, glutathione S-transferase-pull</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-07-15T06:26:40.749Z</modification><creation>2026-07-01T03:07:11.154Z</creation></dates><accession>S-EPMC12336582</accession><cross_references><pubmed>40774693</pubmed><doi>10.1136/jitc-2025-012044</doi></cross_references></HashMap>